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Professional groups, such as IFAPP (International Federation of Pharmaceutical Physicians
and Pharmaceutical Medicine), are expected to produce the defined core competencies to
orient the discipline and the academic programs for the development of future competent
professionals and to advance the profession. On the other hand, PharmaTrain, an
Innovative Medicines Initiative project, has become the largest public-private partnership
in biomedicine in the European Continent and aims to provide postgraduate courses that
are designed to meet the needs of professionals working in medicines development.
A working group was formed within IFAPP including representatives from PharmaTrain,
academic institutions and national member associations, with special interest and
experience on Quality Improvement through education. The objectives were: to define a
set of core competencies for pharmaceutical physicians and drug development scientists,
to be summarized in a Statement of Competence and to benchmark and align these
identified core competencies with the Learning Outcomes (LO) of the PharmaTrain
Base Course. The objectives were successfully achieved. Seven domains and 60 core
competencies were identified and aligned accordingly. The effective implementation
of training programs using the competencies or the PharmaTrain LO anywhere in the
world may transform the drug development process to an efficient and integrated
process for better and safer medicines. The PharmaTrain Base Course might provide the
cognitive framework to achieve the desired Statement of Competence for Pharmaceutical
Physicians and Drug Development Scientists worldwide.
Keywords: competency-based education, learning outcomes, pharmaceutical medicine, core competencies,
pharmaceutical medicine, core competencies, medicines in the 21st century
INTRODUCTION
There is a perceived mismatch between the profile of the grad-
uates from academic programs in health care professions and
the changing needs of the various health systems around the
world. Professional education has not kept pace with these
changes, largely because of fragmented, outdated and static cur-
ricula that produce ill-equipped graduates. Redesign of profes-
sional health education is thus necessary and timely, aiming
for transformative learning and interdependency in education.
(Institute of Medicine, 2002; Josiah Macy Jr. Foundation, 2008;
UK General Medical Council, 2009; Benner et al., 2010; Frenk
et al., 2010; The Association of Faculties of Medicine of Canada,
2010).
Transformative learning involves three fundamental shifts:
(1) from memorizing facts to search, analysis and synthesis
of information for decision-making; (2) from seeking individ-
ual professional credentials to achieving core competencies for
effective teamwork in health systems, and (3) from non-critical
adoption of educational models to creative adaptation of global
resources to address local priorities. Outcomes-Based Education
or Competency-Based Education has been proposed as a suitable
solution for transformative learning. (Dreyfus, 2004; Harden,
2007; Heffron et al., 2007; Gruppen et al., 2010).
Competency based education (CBE) is an emerging discourse in
the health profession’s education and has been adopted by numer-
ous academic institutions and professional associations all over
the world, at the undergraduate, postgraduate and continuing
professional development (CPD) levels.
The definition of CBE is highly variable in the litera-
ture. A systematic review of the medical education litera-
ture related to CBE definition led to the following proposal:
“CBE is an approach to preparing physicians for practice
that is fundamentally oriented to graduate outcome abilities
and organized around competencies derived from an analy-
sis of societal and patient needs. It de-emphasizes time-based
training and promises greater accountability, flexibility and
learner centredness” (Frank et al., 2010a). CBE is organized
around competencies, or predefined abilities, as outcomes of the
curriculum.
Competency is defined as “an observable ability of any pro-
fessional, integrating multiple components such as knowledge,
skills, values, and attitudes.” Since competencies are observable,
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they can be measured and assessed to ensure their acquisition.
Competencies can be assembled like building blocks to facilitate
progressive development. (Frank et al., 2010b)
Given that in the English language “competency” can be used
interchangeably with “competence” (Hager and Gonczi, 1996),
in the medical education and assessment literature the term
“competency” should be restricted to the skill itself, while “com-
petence” is the ability to perform that skill and the attribute of
the performer (Khan and Ramachandran, 2012). Competence
is a point on the spectrum of improving performance. A com-
petent professional is one possessing the required abilities in all
domains in a certain context at a defined stage of education or
practice. Competence and performance are different although
closely interrelated. Performance can be affected by a number of
factors, regardless of competence. (Dreyfus, 2004; Frank et al.,
2010a,b).
There is also a growing realization on the concept of “pro-
gression of competence” meaning that learners advance along
a series of defined milestones on their way to the explicit out-
comes goals of training and can perform as per the expectations
of the employers and the society at large. (Miller, 1990; Khan and
Ramachandran, 2012)
COMPETENCIES IN PHARMACEUTICALMEDICINE/DRUG
DEVELOPMENT SCIENCES
For the past 40 years pharmaceutical medicine has evolved as
a medical scientific discipline for the discovery, development,
evaluation, registration, monitoring and medical marketing of
medicines for the benefits of patients and community health.
Pharmaceutical physicians work in industry, drug regulatory
authorities and clinical research organizations, but have a close
affinity with their medical colleagues in primary and secondary
healthcare and at universities.
As a postgraduate medical discipline, pharmaceutical
medicine has a recognized international syllabus, training
courses with examinations and qualifications, its own research
methodologies and embraces new technologies and regulations
in pursuit and proof of efficacy, safety and effectiveness of
medicines. Organized pharmaceutical medicine is a relatively
young medical specialty. Although there are physicians working
for pharmaceutical companies worldwide, there is limited
awareness of the discipline at the level of the academic and
national medical associations, which has contributed to a slow
uptake in achieving recognition as a medical specialty. Four
countries in Europe: Switzerland, United Kingdom (through
the Faculty of Pharmaceutical Medicine), Belgium (through
the Belgian College of Pharmaceutical Medicine) and Ireland
as well as two in Latin America (Mexico and Argentina) have
accepted Pharmaceutical Medicine as a distinct medical specialty.
In Europe, pharmaceutical medicine is still in its infancy in most
of the countries, and few schools of medicine have a dedicated
curriculum.
About 30 national professional members associations from
countries all over the world are affiliated to IFAPP (International
Table 1 | Domains and desired competencies for the area of drug development and clinical trials.
Domain: discovery of medicines and early development Domain: clinical development and clinical trials
Evaluates and analyses a disease area within the industry clinical
development environment and identifies unmet therapeutic needs
Evaluates the conduct and management of clinical trials within the
context of the Clinical Development Plan and working as part of a Team
Evaluates the clinical and non-clinical pharmacology and toxicology
evidence for a new candidate for clinical development
Designs and executes confirmatory studies and evaluates the resulting
data as applied to the Clinical Development Plan and the TPP
Evaluates and applies the regulatory and ethical aspects underpinning
clinical development
Evaluates and interprets the principles for the development of a clinical
trial protocol applying principles of GCP in clinical pharmacology
Creates a Clinical Development Plan for a new candidate including a
Target Product Profile (TPP)
Summarize the principles of Case Report Form design and clinical data
management, including CDISC, EDC, and MedDRA
Designs and executes exploratory studies and evaluates the resulting
data as applied to the Clinical Development Plan
Organizes the activities and processes related to the selection and
management of sites for individual or multi-center clinical trials
Contrast the advances made in the clinical pharmacology of a new
medicine in a stepwise manner with the overall Clinical Development
Plan and the TPP
Supports and provides the clinical input into the design and review of a
Statistical Analysis Plan
Defends the statistical principles for the design, conduct and
assessment of exploratory studies
Appraises and reviews relevant literature and other sources and writes
manuscripts for publication
Justifies the various end-points used in the clinical development program
Appraises suspected adverse reactions during Exploratory development Interprets and explains the outcomes of clinical studies
IFAPP/PharmaTrain 2012.
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Federation of Associations of Pharmaceutical Physicians and
Pharmaceutical Medicine), a non-profit organization created in
1975 whose main objectives include to foster the development
and international recognition of pharmaceutical medicine as a
separate medical specialty and to foster the development and
training of CME/CPD programs in the discipline. Around 5000
pharmaceutical physicians and other biomedical professionals
involved in drug development are part of the global membership.
(Stonier et al., 2007).
In spite of the fact that pharmaceutical companies are used to
investing heavily in continuingmedical education (CME) or CPD
for health care providers, very few consistent efforts to foster-
ing education and training among their employees (particularly
pharmaceutical physicians) can be cited. This is probably due to
the lack of formal certification (other than the professional qual-
ification) required to work as a physician in the pharmaceutical
industry. On-the-job experience and training on specific top-
ics have been the traditional approach to individual professional
development within pharmaceuticals.
Surveys conducted among 28 IFAPP national member asso-
ciations showed that only 20% of the membership had received
formal postgraduate education in pharmaceutical medicine (Silva
et al., 2012). Similarly, surveys conducted among pharmaceuti-
cal physicians in the USA showed the respondents lacked formal
training in critical areas of drug development (Stonier et al.,
2011).
Professional groups, such as IFAPP, are expected to produce
the defined core competencies to orient the discipline and the
academic programs for the development of future competent
professionals and to advance the profession.
PharmaTrain, an Innovative Medicines Initiative project, is
a Public Private Partnership of 24 Universities, 13 learned
Societies/Associations and several partner training organizations,
including Regulatory Authorities, and 15 pharmaceutical com-
panies affiliated to the European Federation of Pharmaceutical
Industries and Associations (EFPIA). Another 10 universities
from Central Eastern Europe cooperate in the collaborative
European Medicines Development Course, CEMDC, coordi-
nated at Semmelweis University in Budapest. In the last 2
years the nucleus of courses sharing the same standards has
been set-up with an additional group of 12 universities in all
continents.
Table 2 | Domains and desired competencies for the area of regulatory affairs and safety of medicine.
Domain: medicines regulation Domain: drug safety surveillance
Summarizes the legislative framework supporting the development and
registration of medicines, ensuring their safety, efficacy and quality
Contrasts the key regulatory requirements for pharmacovigilance, both
in the major ICH regions and locally, and their historical background
Describes the regulations related to post-authorization safety monitoring
and reporting procedures
Organizes the medical assessments required to meet the requirements
for drug safety reporting both at the level of the individual patient (case
report) and aggregate report
Justifies the significance of regular product Safety Update Reports to
the regulatory agencies and participates in their preparation and review
Summarizes the spontaneous reporting and signal detection
methodologies and assesses medically Adverse Event/Adverse Drug
Reaction reports as part of causality assessment
Evaluates the unlicensed use of medicines and ensures patient safety is
paramount
Summarizes the principles and methods of evaluation of risk and benefit
balance and the principles and methods for managing risk to patient and
clinical trial subjects
Describes procedures in the development and renewal of Marketing
Authorizations
Discriminates the variety of regulatory actions possible to address
concerns about patient safety
Designs, prepares, reviews and evaluates Clinical Overviews for
regulatory submission
Describes the importance of communication of safety issues, the variety
of formats required to meet audience needs and contributes to the
development of such communications
Describes the legal framework for clinical trials and the requirements in
different regions and perceived problems associated with global drug
development
Evaluates a safety issue and establish a crisis management team,
recognizing the key functional areas to be represented and their roles
and responsibilities
Describes the mechanisms for wider availability of medicines, and
undertakes or contributes to product deregulation
Appraises the areas of progress, likely major advances and future
challenges in drug safety and pharmacovigilance
Organizes the investigation of product defects, counterfeit products and
other miscellaneous pharmaceutical procedures and requirements
Describes the principles and process of regulation of medical devices
and biotechnology formulations
IFAPP/PharmaTrain 2012.
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Table 3 | Desired competencies in communication and management
(health care and professionalism area).
Domain: communication and management
Describes the principles and practices of people management and lead-
ership to apply themwithin their own working environment; sets learning
and improvement goals
Ensures that the knowledge, skills and behaviors associated with the
competent practice of pharmaceutical medicine are communicated effec-
tively, using the best techniques and practices whilst participating in the
education of colleagues and stakeholders
Organizes networks and builds and maintains relationships, encourag-
ing contribution and working with interprofessional teams to meet the
business objectives
Supports the success of the organization by actively contributing to
develop strategic plans to achieve goals, manage resources and people,
and leverage performance
Ensures organizational excellence by developing critical evaluation skills,
encouraging improvement and innovation in managing change
Identifies strengths, deficiencies and limits in one’s knowledge and
expertise
Works effectively as a member or leader of a healthcare team or other
professional groups
Explains his/her accountability to key stakeholders, society and the
profession of pharmaceutical medicine
Applies quality and performance improvement concepts to address
organizational performance issues
IFAPP/PharmaTrain 2012.
IFAPP is a founding member of PharmaTrain and has adopted
its syllabus (list of topics comprising a subject, discipline or spe-
cialty field), and curriculum (guideline to transfer the content
of the Syllabus into the modular structure and quality man-
agement system). The curriculum also provides the aims and
objectives, contents, experiences, outcomes and processes of a
program including the methods of learning, teaching, feedback,
and supervision.
PharmaTrain has become the largest public-private partner-
ship in biomedicine in the European Continent. PharmaTrain
aims to provide courses that are designed to meet the needs of
professionals working inmedicines development. Amodular base
Diploma Course, a formal Master’s degree and a CPD platform
provide the opportunities for education and training in Europe.
The quality training program in integrated drug development is
now being standardized by a number of academic organizations
worldwide. (Klech et al., 2012; PharmaTrainManual: curriculum,
PharmaTrainManual, 2012).
The PharmaTrain curriculum is based upon Learning
Outcomes (LO), which are statements of what a student is
expected to know, understand and/or be able to demonstrate after
completion of a process of learning. LOs are an integral part of the
curriculum.
Since most of the current postgraduate programs in
Pharmaceutical Medicine worldwide are knowledge-based, there
is a need to define a core set of competencies that will be help in
the preparation of CBE curricula or to benchmark with the LO of
established curricula, such as those from the PharmaTrain Base
Course.
The objectives for our work were two-fold: (1) to define
a set of core competencies for pharmaceutical physicians and
drug development scientists, to be summarized in a Statement of
Competence; and (2) to benchmark and align these identified core
competencies with the LO of the PharmaTrain Base Course.
METHODS
A working group was formed within the IFAPP’s Council on
Education in Pharmaceutical Medicine (CEPM) including repre-
sentatives from PharmaTrain, academic institutions and IFAPP’s
national member associations, with special interest and expe-
rience on Quality Improvement through education. The group
was also involved in teaching in the discipline at the under-
graduate, postgraduate, and CPD levels. Participants were given
a presentation defining the scope of the project and relevant
definitions. A thorough review and analysis of the core compe-
tencies published by academic groups or professional associations
related to Pharmaceutical Medicine and clinical research was con-
ducted (Batalden et al., 2002; Frank, 2005; Burke et al., 2008;
Calhoun et al., 2008; Joint Royal Colleges of Physicians Training
Board, 2009; Koren et al., 2010; Silva, 2010; Weinberger et al.,
2010; CTSA, 2011; General Medical Council, 2011; Consortium
of Academic Programs in Clinical Research, 2012; Czabanowska
et al., 2012; Klech et al., 2012; Leadership Academy NHS UK,
2013). However, this was not intended to be a systematic review,
but the collection and evaluation of best practices and recommen-
dations related to competencies. A combination of bibliographic
search and individual consultations with related groups was
agreed for this exercise. A modified six-sigma approach was used.
The domains were identified through benchmarking, alignment
and harmonization of domains and competencies from other
similar or related groups. The recommendations from the Joint
Royal College of Physicians Training Board (Joint Royal Colleges
of Physicians Training Board, 2009) were the backbone for this
exercise.
The process can be summarized in three phases. In the first
(identification) 12 domains and 110 competencies were drafted.
After the initial identification of the draft list of domains and
their associated competencies, the group members were asked
to qualify each competency according to its relevance for inclu-
sion in the model, suggest possible changes in the compe-
tency statement, as well as possible changes in the appropriate
domain. The work was conducted via teleconferences and face
to face meetings during the period September 2011–January
2012.
During the second phase (confirmation) the number of
domains and competencies was lowered to 7 and 60 respec-
tively. This second set of proposed domains and competen-
cies and tentative alignment with PharmaTrain LO underwent
another process of expert review and discussions within IFAPP-
CEPM and PharmaTrain. Individual competencies were edited
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Table 4 | Domains and desired competencies in the area of health care and professionalism.
Domain: health care market place Domain: ethics and subject protection
Describes the commercial healthcare environment in which
pharmaceutical medicine operates, identifying the contribution of laws
and of regulators and other stakeholders in the decision making for
prescribing medicines
• Evaluates the impact of cultural diversity and the need for cultural
competency in the conduct of clinical trials and other
business activities
Summarizes the key elements involved in medical/marketing
communication in the healthcare environment and explains the
importance of compliance with regulation in this context
• Describes the ethical and professional issues (conflicts of interest,
plagiarism, authorship and intellectual property) associated with
clinical research, drug development and commercialization on the
production of scientific knowledge
Describes the pharmaceutical industry: internal environment, structure
and function, key stakeholders and commercial drivers and explains how
these business elements impact on the broader healthcare market place
• Describes the significance of historical abuses on the evolution of
principles of human subject protection
Describes the information required to undertake a commercial analysis
of the market potential for a pharmaceutical product/candidate within
the industry business environment
• Evaluates the key documents related to the ethical conduct of clinical
trials and pharmaceutical marketing operations
Appraises the commercial competitor environment when evaluating the
opportunity for new medicine under development or a currently
marketed product
• Describes the ethical issues involved when dealing with vulnerable
populations and the need for additional safeguards
Describes the interface between pharmaceuticals and the external
stakeholder environment and the challenges balancing the commercial
and professional aspects in making ethical judgments within the
legal/regulatory framework
• Compares the requirements for human subject protection and privacy
under different national and international regulations
• Summarizes the principles of Corporate Social Responsibility
IFAPP/PharmaTrain 2012.
and reorganized based upon the recommendations. This process
was extended till May, 2012 and a draft document was prepared.
In the final phase (validation) the draft document was
reviewed by external consultants appointed by both the IFAPP’s
national member associations and PharmaTrain. The second set
of domains and competencies, the statement of competence and
the alignment with PharmaTrain LO was then sent for review
by and feedback from IFAPP’s National Member Associations.
All national associations except one accepted the proposed doc-
ument. The final version was sanctioned at the IFAPP’s General
Assembly held in Barcelona, Spain on November 17, 2012. The
overall initiative was completed within 18 months.
The critical issues considered were: areas and domains for
competency, and its intrinsic and extrinsic validity; the descrip-
tors for each competency and their relevance; the level of granu-
larity and comparability with other professions and disciplines,
and the level of desired expertise. The group focused only in
the cognitive aspects for each proposed competency and con-
ducted a mapping exercise with the LO and Curriculum for the
PharmaTrain Base Course. The competencies were verbalized
using highest wording associated with the competence category
in the revised Bloom’s Taxonomy (Bloom, 1956).
RESULTS
Three areas (Drug Development and Clinical Trials, Regulatory
Affairs and Safety of Medicines, Health Care and Professionalism)
and 7 core competency domains were identified within the
competence framework as follows: Discovery of Medicines
and Early Development; Clinical Development and Clinical
Trials; Medicines Regulation; Drug Safety Surveillance;
Ethics and Subject Protection; Health Care Market Place;
Communication and Management. A total of 60 core compe-
tencies for Pharmaceutical Physicians and Drug Development
Scientists were included within the above mentioned 7 domains
(Tables 1–4).
A Statement of Competence summarizing the competency
domains was prepared (Figure 1). As discussed above, this is a
succinct description for a competent professional able to success-
fully participate in any stage of the product life-cycle manage-
ment.
The LO of the PharmaTrain Base Course were successfully
aligned (93%) with the above mentioned competencies.
DISCUSSION
The competencies are intended to serve as a resource and guide
for those interested in improving the quality and accountability
of pharmaceutical medicine education and training. They were
developed with respect for the uniqueness and diversity in the
complex world of medicines development. Therefore, the model
may foster further granularity and thus identifying specific sub-
competencies and specialty competencies that apply to specific
functions in clinical research and drug development.
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STATEMENT OF COMPETENCE
The Pharmaceutical Physician/Drug Development Scientist:
Is able to identify unmet therapeutic needs, evaluate the evidence for a new candidate 
for clinical development and design a Clinical Development Plan for a Target Product 
Profile.
Is able to design, execute and evaluate exploratory and confirmatory clinical trials and 
prepare manuscripts or reports for publication and regulatory submissions.
Is able to interpret eﬀectively the regulatory requirements for the clinical development 
of a new drug through the product life-cycle to ensure its appropriate therapeutic use 
and proper risk management.
Is able to evaluate the choice, application and analysis of post-authorization surveillance 
methods to meet the requirements of naonal/internaonal agencies for proper 
information and risk minimization to patients and clinical trial subjects.
Is able to combine the principles of clinical research and business ethics for the conduct 
of clinical trials and commercial operations within the organization.
Is able to appraise the pharmaceucal business acvies in the healthcare environment 
to ensure that they remain appropriate, ethical and legal to keep the welfare of patients 
and subjects at the forefront of decision making in the promotion of medicines and 
design of clinical trials.
Is able to interpret the principles and practices of people management and leadership, 
using effecve communication techniques and interpersonal skills to influence key
stakeholders and achieve the scienfic and business objecves.
•
•
•
•
•
•
•
FIGURE 1 | Statement of competence in pharmaceutical medicine. IFAPP/PharmaTrain 2012.
On the other hand, the competencies are anticipated to serve as
a useful guide for education providers (academic or not) to adapt
the related contents in their existing courses so that potential stu-
dents can effectively update their understanding and skills sets in
medicines development. The primary vision for this competency
model is the availability of professionals more fully prepared
for the many challenges and opportunities in pharmaceutical
medicine in the next decade.
Competency-based profiles of key jobs in medicines devel-
opment can be effectively prepared. Standardized job descrip-
tions for various functions could be developed globally. The
effective implementation of training programs using the com-
petencies or the PharmaTrain LO anywhere in the world
may transform the drug development process to an efficient
and integrated process and the product lifecycle management
would turn into the availability of better and safer medicines.
Additionally, it would provide reassurance to stakeholders of
the drug development process that it is in the hands of
competent people who are measured against a set of performance
standards.
Whilst the process model we used to define the core competen-
cies was inclusive, involving all governance bodies within IFAPP
and PharmaTrain as well as key stakeholders within an accept-
able timeframe, only the cognitive aspects were included. Further
work is needed to define the skills and behaviors involved in each
competency. Competency model development are iterative pro-
cesses, and our model will have to be regularly updated as the
competencies are deployed and used for professional, academic or
self-assessment purposes. Continued dialogue regarding the use
of the competencies, their relevancy, and ongoing changes in the
fields of pharmaceutical medicine and other drug development
sciences will make the changes imperative. Competency sets gen-
erally have a life span of 3–5 years (Batalden et al., 2002; Calhoun
et al., 2008) and it will be soon time to revisit the set and ini-
tiate new activities for further refinement and updating in line
with new thinking and future challenges in the field. The model
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cannot remain static. PharmaTrain is rolling out a pilot expe-
rience in establishing the PharmaTrain Specialist in Medicines
Development (www.pharmatrain.eu) based upon the core pro-
fessional competencies.
Other professional groups involved in clinical research are
working to define the roles and competencies of individuals who
work in specific content areas, including physician investiga-
tors, nurses, investigational site staff as well as other professions
involved in regulatory affairs, project management, translational
science and comparative effectiveness (CTSA, 2011; Jones et al.,
2012). Each group is aiming at the same target: better education
of the future workforce of scientists and clinical research person-
nel. The identification and alignment of competencies among the
various groups would give opportunities for inter professional
education as well as the identification of new levels of compe-
tence and would help in defining a career path for pharmaceutical
health professionals.
The general agreement and implementation of core compe-
tencies is essential to the ultimate evolution of accrediting bodies
which will define the standardization of accredited programs for
postgraduate and CPD programs and insure their quality. This
will also result in a definition of what we expect from an entry
level, a mid-level or advanced level professional in drug develop-
ment sciences and will certainly help in the related professional
certification. PharmaTrain and IFAPP should define joint ini-
tiatives to make this happen. Further consultations and proper
feedback from the IFAPP affiliated national member associations
as well as from key experts in the field would be pursued.
In conclusion: A basic set of core competencies and Statement
of Competence are now available for use by IFAPP and serve
as guidance to National Member Associations and individu-
als involved in pharmaceutical medicine and medicines devel-
opment. The PharmaTrain Diploma Base Course might pro-
vide the cognitive framework to achieve the desired Statement
of Competence for Pharmaceutical Physicians and Drug
Development Scientists worldwide and this can be extended by on
the job mentorised CBE for awarding the Specialist in Medicines
Development.
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